Company ProfilePremium

Instituto Rosenbusch S.A.

Company Profile Analysis

Ticker: ROSE.BA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Instituto Rosenbusch S.A. - Company showcase

Year Founded & Workforce

1917

72 Employees

Instituto Rosenbusch S.A. logo

Instituto Rosenbusch S.A. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Instituto Rosenbusch S.A. Overview

Instituto Rosenbusch is a century-old Argentine animal-health laboratory. It develops, manufactures and sells veterinary biologicals (vaccines for cattle, sheep, goats, horses, dogs and cats) and pharmaceuticals (antiparasitics, endectocides, antibiotics, antimastitics, vitamins and minerals). Products are sold mainly to the Argentine livestock sector through a veterinarian-led commercial model, with exports to more than 50 markets. It is the only veterinary biologicals manufacturer listed on the Buenos Aires exchange. The company is in deep financial distress. It went through a concurso preventivo (court-supervised reorganisation) opened in November 2019. It reported a negative gross margin and negative equity at end-2025. In February 2026 control passed from the founding Balestrini family and associated holding companies to Agro 2000 S.A., a Córdoba-origin agribusiness supplier. The new controller is executing a balance-sheet repair (ARS 1.94 bn debt forgiveness plus an ARS 12.3 bn asset revaluation). The investment case now rests on operational turnaround under new ownership rather than on historical franchise strength.


What the company does

Rosenbusch is a vertically integrated veterinary products manufacturer. It owns its product registrations, runs in-house production of both bacterial/viral biologicals and pharmaceutical formulations at its Buenos Aires facility, and sells through its own commercial organisation. Data-vendor descriptions derived from the company's filings divide the portfolio into Biological Products (vaccines for the reproductive-respiratory complex, IBR, BVD, brucellosis, anthrax/carbunclo, clostridial diseases, pneumonia, calf diarrhoea and infectious bovine keratoconjunctivitis; vaccines for sheep, goats, horses and dogs) and Pharmaceutical Products (external and internal antiparasitics, endectocides, antimycotics/bacteriostatics, injectable antibiotics, antimastitics, other chemotherapeutics, vitamins and minerals), plus an Others line ([SA], [TV]).

In addition, the company:

  • markets biolarvicides for environmental control of disease-carrying mosquitoes (dengue, malaria vectors) as an alternative to chemical fumigation ([BdC], [BW]);

  • has developed probiotics aimed at improving bovine gut health and lowering methane emissions ([BdC]);

  • offers specialised diagnostic services ([BdC]);

  • historically was also involved in slaughtering and meat products, according to an older data-vendor profile. Whether that activity continues is not publicly disclosed ([INV]).

Business and revenue model

DimensionCharacterisationEvidence
Revenue modelAlmost entirely product sales (manufactured goods). Service revenue (diagnostics) is not separately disclosed and is believed to be immaterial. No subscription or licensing revenue disclosed.[SA], [BdC]
Product mix FY2025Pharmaceuticals 55.9%, Biologicals 41.1%, Others ~3.0% of salesCompany FY2025 annual report as summarised in [RAVA]
Product mix 9M 2024 (local market)Pharmaceuticals 43.13%, Biologicals 54.76%[BdC]
Market mix FY2025Domestic 68.8%, exports ~31.2%[RAVA]
ChannelCommercial model built on veterinarians based throughout Argentina. The founder believed only veterinarians should sell veterinary products.[BdC], [RAVA] profile
Value-chain positionUpstream manufacturer (R&D, registration, production). Sells to distributors, veterinary practices and producers. Competes with multinational and domestic originators and generic formulators.Analyst assessment
Customer typesCattle ranchers and feedlots (beef and dairy), sheep/goat producers, equine owners, companion-animal veterinary clinics, public-health and municipal vector-control programmes (biolarvicides), export distributors[BdC], [IC], [BW]
End-marketsArgentine livestock health (core); companion animals; vector control; export markets (Latin America, Middle East incl. Libya, Oman, Dubai)[BdC]

Company self-description

The company describes itself, through its long-standing exchange profile, as dedicated exclusively to animal health, run by the third generation of the founding family, with a commercial model built on veterinarians across the country. It also claims a place among Argentina's 300 most important companies and leadership in many market segments, and stresses that it is the only company in its sector listed on the Buenos Aires exchange ([RAVA] profile text). That profile predates the February 2026 change of control. The "third generation of the family" statement is no longer accurate.

Independent characterisation

Analytically, Rosenbusch is a sub-scale, distressed domestic animal-health manufacturer with a heritage brand. Its strengths lie in clostridial, reproductive and anthrax (carbunclo) biologicals, where local registrations, cold-chain distribution and veterinarian relationships matter. In FY2025 it was squeezed between:

  • multinationals (Zoetis, MSD Animal Health, Boehringer Ingelheim, Elanco, Ceva) with far larger R&D budgets; and

  • well-capitalised national laboratories (Biogénesis Bagó, CDV, Over, König, Holliday-Scott).

Revenue at FY2025 levels (≈ ARS 6.4 bn, roughly USD 4–5 M) makes it a micro-cap. Its economics are dominated by working-capital financing costs, FX exposure on imported inputs, and the Argentine inflation/devaluation cycle. The FY2025 collapse in biological sales (−61.4% in pesos) suggests that funding constraints impaired production and supply, rather than a pure demand shock. Management's own commentary cited lack of access to working-capital credit.

Strategy

Stated strategy

No formal strategy document, investor day, or medium-term plan from the new controller is publicly available. The FY2025 annual report, as summarised in [RAVA], states that Agro 2000 has designed an investment plan aimed at repairing the company's delicate financial position and giving it more certainty about the future. Strategic themes identifiable from filings and press:

  1. Balance-sheet restoration. Reverse negative equity to avoid dissolution risk under corporate law and to restore credit access.

  2. Conversion of shareholder credits into equity. The incoming shareholders committed to turning acquired credits into irrevocable capital contributions; the 2026 assembly agenda includes capitalisation of credits from Agro 2000 and the IRSA-named guarantee trust.

  3. Vertical integration into the controller's agribusiness distribution. [IP] notes the acquisition lets Agro 2000 extend into veterinary manufacturing with a brand, registrations, industrial capacity and over a century of history.

  4. Export diversification (Middle East, Latin America), pursued since 2024 ([BdC]).

  5. Innovation niches: biolarvicides for dengue control and methane-reducing bovine probiotics ([BdC]).

Initiatives register (last 24 months)

DateInitiativeTypeQuantificationSource
2024–Jan 2025Export push into Libya, Oman, Dubai via local distributorsMarket expansionExports USD 1.3 M in 9M 2024[BdC]
Pre-2025 (undated)Biolarvicide for mosquito control (dengue)New business / ESG—[BdC]
Pre-2025 (undated)Methane-reducing bovine probioticsR&D / ESG—[BdC]
Feb 2026Agro 2000 investment plan to repair financesTurnaround programmeNot quantified publicly[RAVA]
Feb 2026Commitment to convert former shareholders' credits into irrevocable capital contributionsRecapitalisationNot quantified[RAVA]
11 Sep 2026Agro 2000 irrevocable offer to forgive all intercompany debtRecapitalisationARS 1,941,213,008[RAVA], [IP]
11 Sep 2026Technical revaluation of real estate, machinery and installations; adoption of the IAS 16 revaluation modelAccounting / equity repair+ARS 12,328,258,993 gross; deferred tax ARS 3,082,064,648; net ≈ ARS 9,246 M[RAVA], [IP]
Pending 2026Shareholders' assembly to approve the debt forgiveness and credit capitalisationsCorporate actionCombined equity improvement ≈ ARS 11,187 M[IP]

Guidance

Management has published no financial guidance or medium-term targets. There are no disclosed cost-reduction programmes or ESG targets.

Products & Services

A complete SKU-level catalogue is not publicly available (the company website is offline). The table lists every product or category identifiable from public sources. Launch years and pricing are not publicly disclosed unless stated.

Biological Products

Product / lineDescription and indicationTarget customerSource
Reproductive-respiratory complex vaccines (IBR, BVD and related)Polyvalent vaccines against infectious bovine rhinotracheitis, bovine viral diarrhoea and associated reproductive/respiratory pathogensBeef and dairy herds[SA]
ReprocultivacNamed reproductive-disease vaccine for cattleCow-calf operations[CRAFT]
Brucellosis vaccineVaccine against bovine brucellosis, a regulated disease in ArgentinaCattle producers (official programmes)[SA], [BdC]
Carbunclo (anthrax) vaccineAnthrax vaccine; vaccination compulsory in Buenos Aires and Santa Fe provinces. The company invested in production automation to scale it.Cattle producers in endemic provinces[IC], [BdC]
Clostridial vaccinesPolyvalent vaccines against clostridial diseases (gas gangrene, enterotoxaemia, bacillary haemoglobinuria, etc.)Cattle, sheep, goats[SA], [CRAFT]
Bacillary haemoglobinuria vaccineClostridial vaccineCattle[CRAFT]
Botulism vaccine (types C and D)Toxoid vaccine against botulismCattle[CRAFT]
Tetanus vaccineTetanus toxoidEquines, other livestock[CRAFT]
Pneumonia vaccinesRespiratory disease preventionCalves, feedlot cattle[SA]
Calf-diarrhoea (neonatal) vaccinesDam vaccination to protect calves against neonatal diarrhoeaCow-calf operations[SA]
Infectious bovine keratoconjunctivitis vaccineVaccine against "pink eye"Cattle[SA], [CRAFT]
Equine vaccinesVaccines for horsesEquine owners, studs[SA]
Sheep and goat vaccinesSmall-ruminant vaccinesSheep and goat producers[SA]
Canine vaccinesCompanion-animal vaccinesVeterinary clinics[SA], [BdC]
Cultivac FelinaFeline vaccineVeterinary clinics[CRAFT]

Pharmaceutical Products

Product lineDescriptionTarget customerSource
External antiparasiticsEctoparasiticides (ticks, lice, flies, mange)Livestock and companion animals[SA], [BdC]
Internal antiparasiticsAnthelminticsLivestock and companion animals[SA], [BdC]
EndectocidesCombined internal and external parasite control (macrocyclic-lactone class, per category name)Cattle[SA]
Antimycotics / bacteriostaticsAntifungal and bacteriostatic preparationsLivestock and companion animals[SA]
Injectable antibioticsParenteral antimicrobialsLivestock[SA]
AntimastiticsIntramammary products for bovine mastitisDairy farms[SA]
Other chemotherapeuticsMiscellaneous therapeuticsLivestock[SA]
Vitamins and mineralsNutritional supplements (injectable/oral)Livestock[SA]
Hormonal treatmentsReproductive hormones (listed in older profile)Cattle breeding[INV]

Other offerings

OfferingDescriptionTarget customerSource
BiolarvicidesBiological larvicides for environmental control of mosquitoes that transmit dengue and malaria; a sustainable alternative to fumigationMunicipal and public-health vector-control programmes[BdC], [BW]
Bovine probioticsProbiotics that promote intestinal health in cattle and reduce methane emissionsCattle producers[BdC]
Diagnostic servicesSpecialised veterinary diagnosticsVeterinarians, producers[BdC]

Financial Narrative

All figures are ARS millions (nominal, as captured by [SA] from company filings) unless stated. FY = year to 31 December. See caveat 1: nominal growth is heavily distorted by inflation.

Income statement

Source: [SA], FY2021–FY2025. Company-reported net results differ (FY2023 ARS 789.6 M per [BdC]; FY2024 ARS −1,745 M and FY2025 ARS −4,539 M per company report via [RAVA]).

Per-share data

Source: [SA]. The company has never paid dividends ([TV]). Weighted shares ≈ 42.59 M in all years (no issuance or buybacks).

Margins and growth

Source: [SA]; SG&A ratio computed by analyst. Nominal revenue CAGR FY2021–FY2025 = 43.2% (ARS 1,523 M to 6,404 M). Argentine CPI rose about 95% in 2022, 211% in 2023 and 118% in 2024, so real revenue contracted materially over the period. Company-reported gross margin was 46.3% in FY2024, per the FY2025 annual report ([RAVA]).

Interim and trailing data (FY2026 to date)

Sources: Q1 2026 from [IP] (CNV filing); TTM from [SA]. The positive TTM net income comes entirely from a ARS 2.9 bn tax benefit and a ARS 1.6 bn FX gain. The business still lost money at the operating level (TTM EBIT ARS −3.3 bn).

Balance sheet

Source: [SA]. Discrepancy: [IP] cites the company's 31 Dec 2025 equity as ARS −1,946.5 M (restated to Mar-2026 currency) versus [SA] ARS −526.2 M total equity.

Post-balance-sheet developments (2026):

Sources: Mar-2026 and pro-forma from [IP]; Jun-2026 from [SA]. The Jun-2026 balance sheet appears to already reflect the ARS 12.33 bn technical revaluation (PP&E jumps from ARS 1.65 bn to 14.44 bn) and the related deferred-tax liability within other long-term liabilities (ARS 7.5 bn). The Jun-2026 retained-earnings figure suggests reclassification or absorption of losses against reserves. Detail is not publicly disclosed.

Cash flow

Source: [SA]. TTM to Jun-2026: OCF ARS 973 M, capex ARS 8.9 M, FCF ARS 964 M, net debt repaid ARS 1,364 M.

Ratios

Sources: ROE, ROA, ROIC, current/quick ratios, D/E, net debt/EBITDA, asset and inventory turnover from [SA] (vendor ROA is EBIT-based). Interest coverage, DSO, DIO, DPO and CCC computed by analyst from [SA] year-end balances. FY2025 net debt/EBITDA and D/E are not meaningful (negative EBITDA and equity).

Trend commentary

Revenue. Nominal revenue grew strongly through FY2024 on inflation pass-through. It then fell 41% in FY2025, a period when Argentine inflation decelerated sharply, so the decline was severe in real terms. The company's own breakdown ([RAVA]): domestic sales (68.8% of total) fell 51.6% in pesos; exports fell only 5.1%. Biologicals fell 61.4%, pharmaceuticals 32.1%. Management attributed FY2025 to high costs and difficulty accessing credit for working capital, which prevented it from meeting sales plans. The collapse is therefore largely supply-side: an inability to finance production.

Gross margin. Margins swung between ~28% and ~46% during FY2021–FY2024. That volatility is typical of IAS 29 accounting, where the timing of inventory restatement against price increases distorts cost of sales. FY2025 turned negative (−4.5%) as cost of sales rose 19.8% (input-cost inflation per the company) while volumes collapsed. Fixed manufacturing overhead was then absorbed by far fewer units, a classic operating-deleverage pattern. Q1 2026 remained negative (gross loss ARS 263 M on ARS 1,504 M revenue), and the TTM to June 2026 shows only a marginal positive gross margin (2.7%).

Operating costs. SG&A was essentially flat in nominal pesos in FY2025 (ARS 2,449 M vs 2,428 M) while revenue fell, lifting SG&A/revenue from 22% to 38%. "Other operating expenses" jumped to ARS 634 M, likely provisions or impairments (detail not publicly disclosed).

Financial result. Results are dominated by below-the-line items. Interest expense doubled to ARS 1,651 M in FY2025. FX produced a ARS 3.5 bn loss in FY2024 and gains in FY2023 and FY2025. These swings imply significant USD-denominated liabilities, plausibly concursal debts and import payables, though the currency composition is not publicly disclosed. FY2023's profit relied on a ARS 687 M asset-sale gain and a ARS 1.7 bn FX gain; operating income was only ARS 34 M.

Balance sheet. Equity eroded from ARS 4.5 bn (FY2023) to negative by FY2025, and further to ARS −2.8 bn at Mar-2026 (company basis). Under Argentine company law (Ley General de Sociedades), loss of capital is a ground for dissolution unless remedied, which explains the urgency of the 2026 recapitalisation. Working capital turned negative (ARS −872 M). Accrued expenses more than doubled to ARS 3.85 bn, which likely includes tax and payroll arrears; the FY2025 cash flow shows a ARS 1.87 bn inflow from "change in income taxes", consistent with unpaid tax liabilities.

Cash flow. Operating cash flow stayed positive in every year, but it was largely produced by liquidating working capital (inventory release ARS 1.5 bn in FY2025, ARS 2.1 bn in FY2024) and accruing unpaid liabilities, not by earnings. Capex has been negligible since FY2024 (ARS 12–14 M per year against D&A of ARS 160–190 M), signalling underinvestment in the plant. Debt amortisation (ARS 839 M in FY2025) consumed all FCF, and cash fell 38%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsRepresentative productsSource

Biological Products

Bacterial and viral vaccines for large and small animals

Reproductive-respiratory complex (IBR/BVD), brucellosis, carbunclo (anthrax), clostridial vaccines, equine vaccines, pneumonia and calf-diarrhoea vaccines, keratoconjunctivitis vaccine, canine and feline vaccines

[SA], [TV]

Pharmaceutical Products

Chemical veterinary drugs

External and internal antiparasitics, endectocides, antimycotics/bacteriostatics, injectable antibiotics, antimastitics, other chemotherapeutics, vitamins and minerals

[SA], [TV]

Others

Residual line, likely biolarvicides, diagnostics and miscellaneous items (composition not publicly disclosed)

Biolarvicides, diagnostic services, probiotics (analyst inference)

[TV], [BdC]

Segment revenue (ARS Mn, derived)

Segment revenue (ARS Mn, derived)FY2024FY2025

Pharmaceutical Products

5,2723,580

Biological Products

6,8192,632

Others

349192

Total (derived)

12,4406,404

Segment share of revenue (%)

Segment share of revenue (%)FY2024FY2025

Pharmaceutical Products

42.455.9

Biological Products

54.841.1

Others

2.83.0

Segment YoY growth, nominal ARS (%)

FY2025

—

Pharmaceutical Products

-32.1—

Biological Products

-61.4—

Others

-44.9—

Income Statement

Metric (ARS Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

1,5234,2769,86010,8866,404

Cost of revenue

1,0932,3027,0365,9056,690

Gross profit

429.21,9742,8254,980-286.03

SG&A

397.231,0542,5172,4282,449

Other operating expenses

-10.0144.11273.1791.5634.37

Operating income (EBIT)

41.98875.2734.372,461-3,369

D&A

45.185.72106.89160.55192.08

EBITDA

87.08960.99141.252,621-3,177

Interest expense

67.42524.561,058822.991,651

FX gain (loss)

-114.02-318.061,709-3,504556.45

Gain on sale of assets

00686.6500

Pre-tax income

-38.1132.651,371-1,866-4,463

Income tax expense

8.4374.9134.85245.2950.87

Net income attributable

-38.12-25.221,226-1,864-4,598

Advertising expense

4.349.5521.4316.710.51

Per share (ARS)

Per share (ARS)FY2021FY2022FY2023FY2024FY2025

EPS basic

-0.90-0.5928.78-43.78-107.95

EPS diluted

-0.90-0.5928.78-43.78-107.95

Dividends per share

00000

Book value per share

8.1026.5397.8987.80-18.79

Free cash flow per share

1.271.665.0716.599.34

Margin / growth (%)

Margin / growth (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth (nominal)

80.56180.84130.6110.40-41.17

Gross margin

28.1946.1628.6545.75-4.47

Operating margin

2.7620.470.3522.61-52.61

EBITDA margin

5.7222.481.4324.08-49.61

Net margin

-2.50-0.5912.43-17.13-71.80

SG&A / revenue

26.0824.6525.5322.3038.24

Income Statement (Q1 2026 (3M to 31 Mar)–TTM to 30 Jun 2026)

Metric (ARS Mn)Q1 2026 (3M to 31 Mar)TTM to 30 Jun 2026

Revenue

1,504.26,813

Cost of sales

1,767.46,632

Gross profit

-263.1180.66

Operating income

—-3,308

Net income

-466.3183.57

FX gain

—1,588

Income tax (benefit)

—-2,913

“—” = not publicly disclosed.

Balance Sheet

Balance sheet (ARS Mn, year-end)FY2021FY2022FY2023FY2024FY2025

Cash & equivalents

110.95331.95850.981,154712.26

Receivables (total)

386.071,0352,9692,4261,927

Inventory

580.11,6394,7624,1272,608

Total current assets

1,0833,1188,6177,7585,733

PP&E (net)

361.41,0232,3182,1431,992

Goodwill & intangibles

0.0910.1229.3500

Total assets

1,4564,19810,9819,9217,745

Accounts payable

171.68432.21,797648.73761.78

Accrued expenses

194.96889.75742.441,8733,852

Total current liabilities

542.211,7004,1094,3296,605

Short-term debt (current portion)

36.72152.26948.931,246518.98

Long-term debt

335.29921.911,3021,043931.02

Total debt

372.011,0742,2512,2891,450

Net debt

261.06742.221,4001,135737.74

Total liabilities

1,0682,9516,4345,9318,272

Common equity

344.821,1304,1693,739-800.17

Minority interest

43.18117.44378.59250.87273.98

Total equity

388.011,2474,5483,990-526.19

Working capital

541.061,4184,5093,429-872.37

Balance Sheet (31 Mar 2026–30 Jun 2026)

Balance item (ARS Mn)31 Mar 202630 Jun 2026Pro-forma after Sep-2026 measures (on Mar-26 base)

Total assets

10,801.322,666—

Total liabilities

13,619.914,734—

Total equity

-2,818.67,9328,369

Current assets

5,223.48,010—

Current liabilities

6,908.14,472—

PP&E

1,65414,440—

Accumulated deficit

-10,803.85,413—

“—” = not publicly disclosed.

Cash flow (ARS Mn)

Cash flow (ARS Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

58.37153.37331.37720.31409.89

Capital expenditure

4.1882.63115.4513.6512.13

Free cash flow

54.270.74215.92706.67397.75

Dividends paid

00000

Share buybacks

00000

Net debt repaid

84.184.2987.8672.28839.33

Change in working capital (inflow)

41.48-61.82-1,6101,7914,763

Net change in cash

-29.9-13.55128.1234.39-441.58

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

-15.24-5.1742.68-49.47-260.63

ROA (%)

2.1219.350.2814.71-23.84

ROIC (%)

8.12-85.870.7844.44-107.54

Current ratio (x)

2.001.832.101.790.87

Quick ratio (x)

0.920.800.930.830.40

Debt / equity (x)

0.960.860.500.57-2.76

Net debt / EBITDA (x)

3.000.779.910.43-0.23

Interest coverage EBIT/interest (x)

0.621.670.032.99-2.04

Asset turnover (x)

1.231.511.301.040.73

Inventory turnover (x)

2.122.082.201.331.99

Days sales outstanding

6865576668

Days inventory outstanding

172175166274183

Days payables outstanding

5769934042

Cash conversion cycle (days)

183172130300210

Region revenue (ARS Mn, derived)

Region revenue (ARS Mn, derived)FY2024FY2025

Argentina (domestic)

9,1034,406

Exports (all markets)

2,1051,998

Region share (%)

Region share (%)FY2024FY2025

Argentina (domestic)

81.268.8

Exports

18.831.2

Region growth, nominal ARS (%)

FY2025

—

Argentina (domestic)

-51.6—

Exports

-5.1—

Valuation Snapshot

MetricValuePeriodSource

Export sales

USD 1.3 M

9M to Sep 2024

[BdC]

Export mix — biologicals

65.96%

9M 2024

[BdC]

Export mix — pharmaceuticals

33.65%

9M 2024

[BdC]

Number of export markets

More than 50

Jan 2025

[BdC]

Recently opened markets

Libya, Oman, Dubai (UAE), to be consolidated via local distributors

Jan 2025

[BdC]

Subsidiaries abroad

Paraguay (confirmed 2025); Brazil and Uruguay per aggregator

2011–2025

[BdC], [INV], [BW]

Valuation Snapshot — Last close

MetricValueSource

Last close

ARS 143.50 (6 Oct 2026)

[RAVA]

52-week range

ARS 116.00 – 357.00

[SA]

YTD 2026

−40.33%

[RAVA]

1-year (6 Oct 2025 close ARS 129.00)

+11.2% nominal ARS

[RAVA], analyst computation

3-year (FY2023 close ARS 64.00, approx.)

+124% nominal ARS

[SA], analyst computation

~5-year (FY2021 close ARS 11.00, approx.)

+1,205% nominal ARS (negative or modest in real/USD terms given cumulative inflation and devaluation)

[SA], analyst computation

Beta

0.03 [SA] / 0.41 [RAVA] (illiquid; not meaningful)

[SA], [RAVA]

Average daily volume

≈ 17,000 shares (≈ ARS 2.4 M)

[RAVA]

Year-end price (ARS)

FY2021

FY2022

Closing price

11.0012.90

Market capitalisation (ARS Mn)

468549

Enterprise value (ARS Mn)

615772

Valuation Multiples

Multiple (x)FY2021FY2022FY2023FY2024FY2025

P/E

002.2200

P/S

0.310.130.280.481.60

P/B

1.210.440.601.30-19.47

EV/Sales

0.400.180.330.561.84

EV/EBITDA

7.060.8022.772.320

P/FCF

8.647.7712.627.3525.75

Capital Markets

ItemStatusSource

Dividend history

Never paid

[TV]

Dividend policy

None disclosed; legally constrained by accumulated losses

Analyst

Credit ratings (Moody's / S&P / Fitch / local)

None identified

—

Debt maturity profile

FY2025: current ARS 519 M, non-current ARS 931 M. Jun-2026: current ARS 414 M, non-current ARS 2,654 M (non-current rose, possibly from rescheduling or new controller funding). Detailed schedule not disclosed.

[SA]

Pending dilution

Capitalisation of controller and trust credits (assembly agenda); size not disclosed

[RAVA]

Analyst Conclusions

Guidance and consensus

No management guidance and no sell-side consensus exist. The only forward indicators are (a) the controller's stated intention to execute an investment plan to restore financial health and (b) the balance-sheet measures approved in September 2026. TTM revenue to June 2026 (ARS 6.8 bn) is slightly above FY2025 (ARS 6.4 bn), suggesting stabilisation of the top line but not yet a recovery in real terms. Q1 2026 still showed a gross loss.

Bull case

  1. Balance-sheet reset unlocks working capital. With equity restored (≈ ARS 8 bn) and ARS 1.94 bn of controller debt forgiven, the company can again access trade credit and bank lines. Biologicals revenue, down 61% in FY2025, could recover toward FY2024 levels and restore gross margins of 40%+ seen in FY2022 and FY2024.

  2. Strategic owner with a distribution network. Agro 2000's farm-input reach can push Rosenbusch products through an existing channel at low incremental SG&A. Operating leverage on a fixed SG&A base (≈ ARS 2.4 bn) is substantial.

  3. Deep asset backing. At ARS 6.1 bn market cap against ≈ ARS 14.4 bn of revalued PP&E and positive Jun-2026 equity of ARS 7.9 bn, the stock trades below book (P/B 0.77x). The OPA's financed "fair price" of USD 0.1785 implies roughly 85% upside to the ~USD 0.096 market-implied price.

Bear case

  1. Revaluation is not cash. About ARS 9.2 bn of the ≈ ARS 11.2 bn equity improvement is a non-cash accounting remeasurement. The operating business lost ARS 3.3 bn at EBIT level in the TTM to June 2026, and the Q1 2026 gross margin was negative.

  2. Minority value leakage. The OPA offered either 17-year deferred payment or a cash price (~USD 0.08) below market. Capitalisation of controller credits could dilute minorities. A future delisting could strand the 19.84% float.

  3. Structural competitive disadvantage. Years of near-zero capex, no disclosed R&D, and FMD-deregulation-driven price competition led by a national champion (Biogénesis Bagó) heading toward USD 300 M of revenue leave Rosenbusch exposed in its core biologicals franchise.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Shareholders' assembly approving debt forgiveness and credit capitalisationQ4 2026Determines final equity and minority dilution
Q3 2026 resultsVendor estimate 17 Dec 2026First full quarter under the new balance sheet; watch gross margin
FY2026 annual report~Apr 2027Full-year turnaround evidence; auditor opinion on going concern
BYMA trading regimeOngoingRemoval of "special warnings" status would signal normalised disclosure
Capital increase or rights offeringUndeterminedFresh cash versus non-cash restructuring
Delisting decisionUndeterminedMinority liquidity risk
Biologicals production restart (volumes, export orders)2026–27Core franchise recovery
Management appointments and strategy disclosure from Agro 20002026–27Visibility on plan, capex and targets

Analyst verdict

Instituto Rosenbusch is a heritage Argentine animal-health brand emerging from an operational and financial collapse under new ownership. The FY2025 numbers are as bad as industrial accounts get: revenue down 41%, a negative gross margin, a net loss larger than 70% of sales, and negative equity. Q1 2026 confirmed that losses had not stopped at the time of the takeover. Positive operating cash flow over the past five years was largely a liquidation of inventory and an accumulation of unpaid liabilities, not proof of earnings power.

The September 2026 measures change the legal and accounting picture more than the economic one. Forgiving ARS 1.94 bn of intercompany debt is a real transfer from the controller. The ARS 12.3 bn revaluation, by contrast, simply recognises that an owned urban plant and its equipment were carried far below replacement value. Together they remove the immediate capital-loss threat and make the company financeable. Neither puts cash into production of vaccines or antiparasitics. The turnaround thesis therefore rests on three unproven premises: that Agro 2000 will inject working capital (directly or through credit lines enabled by the new balance sheet); that biologicals production can be restored at competitive cost in an increasingly open market; and that the controller's distribution footprint can rebuild domestic share.

For minority investors, the governance record since February is a material negative. The OPA offered a 17-year instalment plan or a cash price below the market, and no holder accepted. Further dilution through credit capitalisation remains possible. The stock trades below revalued book, which is defensible given the uncertainty.

Verdict: Speculative turnaround. Upgrading this view would require two consecutive quarters of positive gross margin, disclosure of a funded capex and working-capital plan, and clarity on credit-capitalisation terms. Absent these, the market-implied ~USD 4 M equity value appears a fair reflection of a distressed option on a brand and a building.


*End of dossier. All figures in ARS unless stated; USD conversions are approximate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / contextSource

Félix Agustín Gaibisso

President of the Board

In office by Sep 2026 (signed Hecho Relevante of 11 Sep 2026); presumed appointed after the Feb 2026 change of control

[RAVA]

Dr. Rodolfo Martín Balestrini

Former Chairman of the Board and President (still listed by data vendors)

Pre-2026 family leadership; status after the sale not publicly disclosed

[SA], [INV]

Oscar Echeverria

Financial Manager (per data vendor)

—

[SA]

Andrés Balestrini

Director (historical)

Since 2006

[INV]

Mónica Eva Lukesch

Director (historical)

—

[INV]

Ramón Antonio Maynard

Member, Supervisory Committee (Comisión Fiscalizadora) (historical)

—

[INV]

Armando Manuel Silvariño

Member, Supervisory Committee (historical)

—

[INV]

José Carlos Rognoni

Member, Supervisory Committee (historical)

—

[INV]

“—” = not publicly disclosed.

Governance Overview

ItemStatusSource

Audit Committee

Exists; issued a favourable prior opinion on the Agro 2000 debt-forgiveness proposal (Sep 2026)

[IP], [RAVA]

Supervisory Committee (Comisión Fiscalizadora)

Exists (historically three members)

[INV]

Board meeting minute numbering

Minute No. 1401 (11 Sep 2026)

[RAVA]

Independence ratio

Not publicly disclosed (CNV rules require independent members on the Audit Committee)

—

Chair/CEO separation

Historically combined (the Chairman was also President, the executive role in Argentine S.A.s); post-2026 not disclosed

[SA]

Dual-class structure

Class A shares (5 votes) and Class B (1 vote). Only 192 Class A shares are in the free float; Class A held by the controller is not disclosed.

[RAVA]

Board & Management Changes

DateChangeContext

10 Feb 2026

Control passes from Rinder, San Teobaldo and Balestrini family members to Agro 2000 S.A. (80.16%)

Ends roughly a century of founding-family control. The sale included all credits the former shareholders held against the company. The new shareholders committed to converting these into irrevocable contributions toward future capital increases. [IP], [RAVA]

2026 (date not disclosed)

Félix Agustín Gaibisso becomes President

New controller's nominee (analyst inference)

Major Shareholders

HolderShares (approx.)StakeSource

Agro 2000 S.A. (Córdoba-origin agribusiness inputs and services company)

34.14 M

80.16%

[IP], [RAVA]

Free float (public; individual holders not disclosed)

8.45 M

19.84%

[RAVA]

Competitive Landscape

Key Competitors

CompetitorOwnership / typeOverlapping segmentsScale and positioningSource

Biogénesis Bagó

Argentine private (Bagó group / Insud)

Biologicals (FMD, rabies, clostridial, reproductive), pharmaceuticals, companion animals

Dominant national biologicals player: decades as main FMD vaccine supplier (~100 M doses/yr in Argentina), antigen-bank supplier to Argentina, US, Canada, Korea, Taiwan, and Brazil (Dec 2025). CEO targets USD 300 M revenue by 2027.

bichosdecampo.com; mercado.com.ar

Centro de Diagnóstico Veterinario (CDV)

Argentine private

Biologicals (FMD and others), diagnostics

More than 60 products exported to 30 markets; minority FMD share

bichosdecampo.com

Tecnovax

Argentine private

Biologicals (FMD entrant via Brazilian supply, cattle vaccines)

Challenger in the deregulated FMD market

bichosdecampo.com

Over (Laboratorios Over)

Argentine private

Pharmaceuticals (antiparasitics, antibiotics), exports

Strong national exporter

[BdC] related coverage

Laboratorios König

Argentine private

Pharmaceuticals, companion animals

National mid-size player (financials not publicly disclosed)

Analyst knowledge

Holliday-Scott

Argentine private

Pharmaceuticals (antiparasitics, endectocides)

National mid-size player (financials not publicly disclosed)

Analyst knowledge

Zoetis

US-listed multinational

Livestock and companion-animal biologicals and pharmaceuticals

—

Analyst knowledge

MSD Animal Health (Merck & Co.)

Multinational

Biologicals, antiparasitics

Global top-3

Analyst knowledge

Boehringer Ingelheim Animal Health

Multinational (private parent)

Biologicals, endectocides

Global top-3

Analyst knowledge

Elanco

US-listed multinational

Pharmaceuticals, parasiticides

—

Analyst knowledge

Ceva Santé Animale

French private

Biologicals, reproduction

Strong in ruminant reproduction and LatAm vaccines

Analyst knowledge

Valent BioSciences / other Bti larvicide suppliers

Multinational

Biolarvicides (vector control)

Global leaders in biological mosquito control

Analyst knowledge

Peer Comparison FY2025

MetricRosenbusch FY2024Rosenbusch FY2025Zoetis FY2024Elanco FY2024Biogénesis Bagó

Revenue

≈ USD 11 M (ARS 10,886 M)

≈ USD 5 M (ARS 6,404 M)

≈ USD 9,300 M

≈ USD 4,400 M

Not disclosed (target USD 300 M by 2027)

Revenue growth (local currency)

+10.4% nominal ARS (negative real)

−41.2% nominal ARS

≈ +8%

≈ +1%

~14%/yr in FMD and rabies over the prior three years (per CEO)

Gross margin

45.8%−4.5%

≈ 70%

≈ 55%

—

Operating (EBIT) margin

22.6%−52.6%

≈ 36%

Low single digit (GAAP)

—

R&D intensity

——

≈ 7% of revenue

≈ 8% of revenue

—

“—” = not publicly disclosed.

Recent Developments

Every identifiable material item is listed (fewer than the 25 requested; no further items were found).

Company Snapshot

72

Employees

$4.1M

Market Cap

1917

Founded

SWOT Analysis

Strengths

  • Deep heritage and brand trust in animal health: Origins in the 1917 SRA Instituto Biológico; formal S.A. since 1946; founder honoured as a leading veterinary scientist ([BdC])
  • Owned industrial real estate and plant with substantial latent value: Technical revaluation of ARS 12.33 bn at 30 Jun 2026 versus book PP&E of ARS 1.65 bn at Mar-2026 ([RAVA], [IP])
  • Committed controlling shareholder: Agro 2000 offered to forgive ARS 1.94 bn of debt irrevocably and committed to converting acquired credits into capital contributions ([RAVA])
  • Resilient export channel: FY2025 exports fell only 5.1% while domestic sales fell 51.6%; exports reached 31.2% of sales ([RAVA])
  • Broad registered portfolio across biologicals and pharmaceuticals: Vaccines for cattle, sheep, goats, horses, dogs, cats; full antiparasitic, antibiotic and antimastitic range ([SA])
  • Positive operating cash flow in each of the last five years: OCF ARS 58 M to 720 M (FY2021–FY2025); TTM Jun-2026 OCF ARS 973 M ([SA])
  • Differentiated niche innovations: Biolarvicides for dengue-vector control; methane-reducing bovine probiotics ([BdC])

Weaknesses

  • Negative gross margin: FY2025 gross margin −4.5%; Q1 2026 gross loss ARS 263 M on ARS 1,504 M revenue ([SA], [IP])
  • Negative equity and accumulated losses: Equity ARS −2,818.6 M at 31 Mar 2026; accumulated deficit ARS −10,803.8 M ([IP])
  • Liquidity strain: Current assets ARS 5,223 M vs current liabilities ARS 6,908 M (Mar-2026); FY2025 current ratio 0.87, quick ratio 0.40 ([IP], [SA])
  • Chronic under-investment: Capex ARS 12.1 M in FY2025 (0.19% of revenue) vs D&A ARS 192 M ([SA])
  • Opaque and late disclosure: Q1 2026 statements published 6 Aug 2026; BYMA "special warnings" classification; company website offline ([RAVA])
  • Cash-flow quality depends on working-capital liquidation: FY2025 OCF of ARS 410 M was driven by ARS 4.76 bn working-capital release (inventory −ARS 1.5 bn, tax accruals +ARS 1.9 bn) against a ARS 4.6 bn net loss ([SA])
  • Heavy financing burden: Interest expense ARS 1,651 M in FY2025, about 26% of revenue ([SA])

Opportunities

  • Restored balance sheet enables credit access and capital raising: Pro-forma equity ≈ ARS 8.4 bn after forgiveness and revaluation ([IP]); Jun-2026 equity ARS 7.9 bn ([SA])
  • Channel synergies with the controller's agribusiness network: Agro 2000 supplies products and services to the farm sector; the acquisition adds veterinary manufacturing with brand and registrations ([IP])
  • Rebuild biologicals volumes from a depressed base: Biologicals fell 61.4% in FY2025. The FY2024 level (≈55% of sales) shows the earlier capacity to sell. ([RAVA], [BdC])
  • Export growth in new geographies: Recent entry to Libya, Oman, Dubai; more than 50 markets served ([BdC])
  • Public-health demand for vector control: Dengue-vector biolarvicide as a sustainable alternative to fumigation ([BdC])
  • Climate-linked livestock products: Methane-reducing probiotics align with beef-export decarbonisation demands ([BdC])
  • Compulsory anthrax vaccination: Carbunclo vaccination compulsory in Buenos Aires and Santa Fe; the company invested in automation to lead the segment ([IC])

Threats

  • Intensifying competition in national biologicals after deregulation: FMD vaccine market opened in 2024–25; Biogénesis Bagó cut price 23%; new entrants such as Tecnovax (bichosdecampo.com)
  • Scale gap versus the national leader: Biogénesis Bagó targets USD 300 M revenue by 2027 versus Rosenbusch's ≈ USD 5 M in FY2025 (press; [SA])
  • Minority dilution and governance risk: Capitalisation of controller credits on the assembly agenda; OPA paid over 17 years drew minority criticism and zero acceptances ([RAVA])
  • Dissolution or insolvency relapse if repair stalls: Negative equity triggers legal capital-loss provisions; the company only recently exited concurso (opened Nov 2019) ([IP])
  • Macro and FX volatility: FX loss ARS 3.5 bn in FY2024; FX gain ARS 1.7 bn in FY2023 ([SA])
  • Possible delisting reduces minority liquidity: Market speculation after the OPA; float only 19.84% ([RAVA])
  • Input-cost inflation: FY2025 cost of sales rose 19.8% on input-cost increases while sales fell 41% ([RAVA], [SA])

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (throughout)Argentina's FMD vaccine market deregulated (tetravalent to bi/trivalent; new entrants such as Tecnovax). Leader Biogénesis Bagó cut its FMD vaccine price 23%. bichosdecampo.com (2024–25)Intensifies price competition and capital availability in national biologicals; Rosenbusch is not a material FMD player
Oct–Nov 2025ROSE rallies from ~ARS 117 (22 Oct) to an intraday ARS 357 (21 Nov) on very high volumes (up to ~780k shares/day), then retraces [RAVA], [SA]Likely speculation about a control transaction; no company explanation found
Q4 2025 / FY2025Revenue −41%, negative gross margin, net loss ≈ ARS 4.5–4.6 bn, negative equity [SA], [RAVA]Confirms acute distress
10 Feb 2026Agro 2000 acquires 80.16% from Rinder, San Teobaldo and Balestrini family [IP], [RAVA]Change of control; triggers mandatory OPA
Feb 2026Buyer commits to converting acquired credits into irrevocable capital contributions; announces a financial-repair investment plan [RAVA]Signals recapitalisation intent
26 Mar 2026CNV Resolution RE-2026-28721963-APN-GE#CNV exempts the OPA from the six-month average-price test due to the concursal situation [RAVA]Allows the OPA at the negotiated price only
Mar–Apr 2026Share falls from ~ARS 216 (10 Mar) to ARS 133.5 (27 Mar), then rebounds to ARS 199 (7 Apr) [RAVA]Volatility around OPA terms
~13 Apr 2026FY2025 annual report (79th fiscal year) filed: net loss ARS 4,539 M; equity negative [RAVA]Formal disclosure of FY2025 collapse
14 Apr 2026Independent valuation: USD 0.06325/share (Lisicki Litvin & Abelovich) [RAVA]Benchmark for OPA cash option
16 Apr 2026Complementary OPA announcement (file EX-2026-24777957--APN-GE#CNV) sets the highest agreed price at USD 0.1785/share; no other purchases in the prior 12 months [RAVA]Defines the "fair price"
Apr 2026Minority-shareholder criticism of the instalment-based OPA terms [RAVA]Governance and reputational friction
2026 (various)BYMA places ROSE under "trading with special warnings"; several trading interruptions and resumptions [RAVA]Signals regulatory concern over financial condition and disclosure
6 Aug 2026Q1 2026 financial statements published (≈4 months after quarter end): revenue ARS 1,504 M, gross loss ARS 263 M, net loss ARS 466 M, equity ARS −2,819 M [RAVA], [IP]Late filing; continued losses under new owner
Aug 2026Community reports that BCRA data show several previously rejected cheques were cleared [RAVA]Possible sign of supplier-credit normalisation
26 Aug 2026Technical revaluation report issued (as of 30 Jun 2026) [RAVA]Basis for equity restoration
3 Sep 2026OPA prospectus and definitive announcement: financed (USD 0.1785) or cash (~USD 0.08) options [RAVA]Minority exit route
11 Sep 2026Hecho Relevante: board approves ARS 12.33 bn revaluation and IAS 16 revaluation model; Agro 2000 offers to forgive ARS 1.94 bn [RAVA], [IP]Equity turns positive pro-forma (~ARS 8.4 bn)
14 Sep 2026iProfesional publishes detailed analysis of the rescue plan [IP]Wider market awareness
15 Sep 2026[SA] data update shows Jun-2026 balance sheet with equity ARS 7.9 bn and PP&E ARS 14.4 bnRevaluation appears reflected in H1 2026 accounts
17 Sep 2026Complementary OPA announcement [RAVA]Final terms adjustment
18 Sep 2026OPA closes; no shareholder accepted [RAVA]Minorities retain 19.84%; float unchanged
6 Oct 2026Share closes ARS 143.50; YTD −40.3% [RAVA]Market remains sceptical
Est. 17 Dec 2026Next earnings release (vendor estimate) [SA]Q3 2026 results

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from ARS 1,523 Mn in FY2021 to ARS 6,404 Mn in FY2025.
Instituto Rosenbusch S.A. — Income Statement: Revenue & Gross Profit
Series (ARS Mn)FY2021FY2022FY2023FY2024FY2025
Revenue1,5234,2769,86010,8866,404
Cost of revenue1,0932,3027,0365,9056,690
Gross profit429.21,9742,8254,980-286

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.